AU2006337137B2 - Multicyclic amino acid derivatives and methods of their use - Google Patents
Multicyclic amino acid derivatives and methods of their use Download PDFInfo
- Publication number
- AU2006337137B2 AU2006337137B2 AU2006337137A AU2006337137A AU2006337137B2 AU 2006337137 B2 AU2006337137 B2 AU 2006337137B2 AU 2006337137 A AU2006337137 A AU 2006337137A AU 2006337137 A AU2006337137 A AU 2006337137A AU 2006337137 B2 AU2006337137 B2 AU 2006337137B2
- Authority
- AU
- Australia
- Prior art keywords
- amino
- phenyl
- propanoic acid
- pyrimidin
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75495505P | 2005-12-29 | 2005-12-29 | |
US60/754,955 | 2005-12-29 | ||
PCT/US2006/047579 WO2007089335A2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006337137A1 AU2006337137A1 (en) | 2007-08-09 |
AU2006337137B2 true AU2006337137B2 (en) | 2012-06-14 |
Family
ID=38327831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006337137A Active 2031-12-12 AU2006337137B2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
Country Status (21)
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
ZA200805192B (en) * | 2005-12-29 | 2009-11-25 | Lexicon Pharmaceuticals Inc | Multicyclic amino acid derivatives and methods of their use |
US7855291B2 (en) * | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
LT2848610T (lt) * | 2006-11-15 | 2017-11-10 | Ym Biosciences Australia Pty Ltd | Kinazės aktyvumo inhibitoriai |
UA99270C2 (en) | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
KR20100037047A (ko) | 2007-06-26 | 2010-04-08 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 세로토닌-매개 질환 및 장애의 치료 방법 |
US8093291B2 (en) * | 2007-06-26 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
CA2693400A1 (en) * | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
KR20100055436A (ko) * | 2007-07-26 | 2010-05-26 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 위장관 통과 및 위 배출에 영향을 주는 방법, 및 그에 유용한 화합물 |
WO2009029499A1 (en) * | 2007-08-24 | 2009-03-05 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
US20100260772A1 (en) * | 2007-09-28 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
AU2009212462B2 (en) * | 2008-02-04 | 2012-09-13 | Mercury Therapeutics, Inc. | AMPK modulators |
US8759364B2 (en) * | 2008-03-31 | 2014-06-24 | The Trustees Of Columbia University In The City Of New York | Methods of treating bone mass diseases |
US20100022549A1 (en) * | 2008-07-23 | 2010-01-28 | The Scripps Research Institute | Alpha-helix mimetic with functionalized pyridazine |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
EP2344160A1 (en) * | 2008-10-03 | 2011-07-20 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors and methods of their use |
EP2358685A1 (en) * | 2008-10-24 | 2011-08-24 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
WO2010062829A1 (en) * | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
WO2011053977A1 (en) | 2009-11-02 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
EP2496231A1 (en) * | 2009-11-05 | 2012-09-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
WO2011063072A2 (en) | 2009-11-19 | 2011-05-26 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US20120077831A1 (en) * | 2009-11-23 | 2012-03-29 | Philip Manton Brown | Methods and assays for the treatment of irritable bowel syndrome |
CA2780979A1 (en) * | 2009-11-23 | 2011-05-26 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
JP2013519673A (ja) | 2010-02-10 | 2013-05-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤 |
TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
JP2013530180A (ja) | 2010-06-16 | 2013-07-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | アリール置換インドールおよびその使用 |
CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
TW201245183A (en) * | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
GB201203793D0 (en) * | 2012-03-05 | 2012-04-18 | Ge Healthcare Ltd | Imaging neural activity |
WO2013148978A1 (en) | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
EP3071567B1 (en) | 2013-11-19 | 2017-09-06 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
AR098436A1 (es) * | 2013-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Compuestos tricíclicos de piperidina |
WO2015089137A1 (en) * | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
EP3135667A4 (en) | 2014-04-24 | 2017-11-01 | Mitsubishi Tanabe Pharma Corporation | Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2016097001A1 (en) | 2014-12-17 | 2016-06-23 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
WO2016109501A1 (en) * | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
JP2016204314A (ja) * | 2015-04-23 | 2016-12-08 | 国立研究開発法人理化学研究所 | 化合物及び4−ボロノフェニルアラニン誘導体の製造方法 |
MA42034A (fr) | 2015-05-04 | 2018-03-14 | Actelion Pharmaceuticals Ltd | Composés pipéridiniques tricycliques |
IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
WO2019039905A1 (ko) | 2017-08-24 | 2019-02-28 | 광주과학기술원 | 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112906A2 (en) * | 2004-05-21 | 2005-12-01 | Duke University | Method for augmenting the effects of serotonin reuptake inhibitors |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH471146A (de) | 1966-03-16 | 1969-04-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen Morpholinderivaten |
US4866181A (en) | 1986-08-29 | 1989-09-12 | Aldrich-Boranes, Inc. | Process for producing optically active alcohols |
US4916074A (en) | 1986-10-30 | 1990-04-10 | Chisso Corporation | Process for producing optically active compounds |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0504541B1 (en) | 1991-03-21 | 1998-07-22 | Solutia Europe N.V./S.A. | Improved catalytic process for selective alkylation of aromatic hydrocarbons |
DE4131924A1 (de) | 1991-09-25 | 1993-07-08 | Hoechst Ag | Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
WO1995014683A1 (en) | 1993-11-24 | 1995-06-01 | The Du Pont Merck Pharmaceutical Company | Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
GB9518553D0 (en) | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
ATE212990T1 (de) | 1996-03-20 | 2002-02-15 | Hoechst Ag | Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten |
US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
DE69836279T2 (de) | 1997-08-20 | 2007-05-31 | Kyowa Medex Co. Ltd. | Neue Verbindung, 2-Amino-3-[2-(α-Mannopyranosyl)indol-3-YL] Propionsäure, Verfahren zur Herstellung und Methoden zur in Vivo Untersuchung mit der neuen Verbindung |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
SK13312000A3 (sk) * | 1998-03-27 | 2001-05-10 | Pharmacia And Upjohn Company | Použitie kabergolínu pri liečbe syndrómu nepokojných nôh |
US6423727B1 (en) | 1998-04-23 | 2002-07-23 | Novartis Ag | Certain thiol inhibitors of endothelin-converting enzyme |
WO2000019994A1 (en) | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
JP2000204085A (ja) | 1998-11-13 | 2000-07-25 | Nippon Bayer Agrochem Co Ltd | イソチアゾ―ルカルボン酸誘導体および病害防除剤 |
US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
SK8432001A3 (en) * | 1998-12-16 | 2001-12-03 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
IL144636A0 (en) | 1999-02-18 | 2002-05-23 | Hoffmann La Roche | Thioamide derivatives |
TR200102944T2 (tr) | 1999-04-13 | 2002-08-21 | Basf Aktiengesellschaft | İntegrin reseptör ligandları |
US7045532B2 (en) * | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
JP4156807B2 (ja) | 1999-06-01 | 2008-09-24 | エラン ファーマ インターナショナル,リミティド | 小型ミル及びその方法 |
EP1065208A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
US6420418B1 (en) | 1999-08-16 | 2002-07-16 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
IL148544A0 (en) | 1999-09-24 | 2002-09-12 | Genentech Inc | Tyrosine derivatives |
MXPA02003419A (es) | 1999-10-06 | 2002-10-17 | Basf Ag | Moduladores de las vias de senalizacion mediadas por citocina y antagonistas de los receptores para integrina alfav°3 para tratamiento en combinacion. |
DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
WO2001030333A2 (en) | 1999-10-27 | 2001-05-03 | Sunol Molecular Corporation | Tissue factor antagonists and methods of use thereof |
ATE355269T1 (de) | 1999-11-18 | 2006-03-15 | Ajinomoto Kk | Phenylalaninderivate |
US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
YU41202A (sh) | 1999-12-28 | 2005-03-15 | Pfizer Products Inc. | Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti |
EP1251730A4 (en) | 2000-01-26 | 2004-10-20 | Univ Kansas State | PRODUCTION AND USE OF POLYMERS CROSSLINKED WITH TYROSINE CONTAINING PEPTIDES |
FR2804427B1 (fr) | 2000-01-27 | 2002-09-06 | Rhodia Chimie Sa | Procede de preparation de cetones alpha-halogenees |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
NZ523428A (en) | 2000-06-28 | 2008-03-28 | Prana Biotechnology Ltd | Neurotoxic oligomers |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7015216B2 (en) | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
US6689781B2 (en) | 2000-07-21 | 2004-02-10 | Elan Pharmaceuticals, Inc. | Phenylalanine derivatives as alpha 4 integrin inhibitors |
WO2002016329A1 (fr) | 2000-08-18 | 2002-02-28 | Ajinomoto Co., Inc. | Nouveaux derives de phenylalanine |
DE10042655A1 (de) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
MY129000A (en) * | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
AU2001290303A1 (en) | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
WO2002074743A1 (fr) | 2001-03-19 | 2002-09-26 | Dainippon Pharmaceutical Co., Ltd. | Compose alicyclique a substitution aryle et composition medicale contenant ce compose |
DE60208186T2 (de) | 2001-04-09 | 2006-08-24 | Ortho-Mcneil Pharmaceutical Research Inc. | Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen |
EP1461425B1 (en) | 2001-05-29 | 2008-02-13 | Lexicon Pharmaceuticals, Inc. | Novel human hydroxylases and polynucleotides encoding the same |
US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
JP4223390B2 (ja) | 2001-06-05 | 2009-02-12 | エラン・ファルマ・インターナショナル・リミテッド | 材料をフライス削りするシステムおよび方法 |
US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
WO2003053926A1 (fr) | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Nouveau derive de phenylalanine |
US20030171368A1 (en) | 2002-02-06 | 2003-09-11 | Werner Seitz | Pyrimidinonesulfamoylureas` |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
EP1492780B1 (en) | 2002-04-03 | 2011-11-23 | Novartis AG | 5-substituted 1,1-dioxo-¬1,2,5 thiazolidine-3-one derivatives as ptpase 1b inhibitors |
WO2003089410A1 (fr) | 2002-04-19 | 2003-10-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de phenylalanine |
WO2003104200A1 (en) | 2002-06-07 | 2003-12-18 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
GB0213122D0 (en) | 2002-06-07 | 2002-07-17 | Glaxo Group Ltd | Compounds |
DE10226921A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Antibakterielle Amid-Makrozyklen |
DE10234422A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Antibakterielle Ester-Makrozyklen |
EP1546089A2 (en) | 2002-08-09 | 2005-06-29 | TransTech Pharma Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
US20050260126A1 (en) | 2002-08-30 | 2005-11-24 | Yukitsuka Kudo | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
DK1553927T3 (da) | 2002-09-11 | 2011-01-31 | Elan Pharma Int Ltd | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger |
AU2003301903A1 (en) | 2002-11-06 | 2004-06-03 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
RU2005119167A (ru) | 2002-11-19 | 2006-01-20 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | Новые биароматические соединения-активаторы рецепторов типа ppary и их применение в косметических или фармацевтических композициях |
ZA200504898B (en) * | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
ITMI20022738A1 (it) | 2002-12-23 | 2004-06-24 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4. |
ATE412657T1 (de) | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
EP1604971A4 (en) | 2003-03-11 | 2006-08-16 | Ono Pharmaceutical Co | PROCESS FOR ADDING ACTIVE CHARCOAL IN WATER PURIFICATION AND WATER PURIFICATION METHOD |
US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
EP1615926A1 (en) | 2003-04-21 | 2006-01-18 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (purin-6-yl) amino acid and production method thereof |
MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
EP1638964B1 (en) | 2003-06-20 | 2011-07-27 | Galderma Research & Development | Novel compounds that modulate ppar-gamma type receptors, and use thereof in cosmetic or pharmaceutical compositions |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
CA2540646A1 (en) | 2003-10-01 | 2005-04-14 | Bayer Healthcare Ag | Antibacterial amide macrocycles |
WO2005035551A2 (en) | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
MXPA06004642A (es) | 2003-11-05 | 2006-06-27 | Hoffmann La Roche | Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar). |
DE10358824A1 (de) | 2003-12-16 | 2005-07-21 | Bayer Healthcare Ag | Antibakterielle Makrozyklen mit substituiertem Biphenyl |
EP2615087A3 (en) | 2003-12-22 | 2013-08-07 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
WO2005069845A2 (en) | 2004-01-14 | 2005-08-04 | Ohio University | Methods of producing peptides/proteins in plants and peptides/proteins produced thereby |
JP2007126358A (ja) | 2004-01-20 | 2007-05-24 | Fujiyakuhin Co Ltd | フェニルアラニン誘導体 |
WO2005076972A2 (en) | 2004-02-05 | 2005-08-25 | The Ohio State University Research Foundation | Chimeric vegf peptides |
JP2007522225A (ja) | 2004-02-10 | 2007-08-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | A4インテグリン拮抗薬としてのピリダジノン |
US20070265345A1 (en) | 2004-07-27 | 2007-11-15 | Smithkline Beecham Corporation | Novel Biphenyl Compounds And Their Use |
JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
ZA200805192B (en) * | 2005-12-29 | 2009-11-25 | Lexicon Pharmaceuticals Inc | Multicyclic amino acid derivatives and methods of their use |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
US8093291B2 (en) * | 2007-06-26 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
CA2693400A1 (en) * | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
TWI439457B (zh) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法 |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
-
2006
- 2006-12-12 ZA ZA200805192A patent/ZA200805192B/xx unknown
- 2006-12-12 EP EP06849951A patent/EP1984344B1/en active Active
- 2006-12-12 UA UAA200809740A patent/UA96936C2/uk unknown
- 2006-12-12 ES ES06849951T patent/ES2395392T3/es active Active
- 2006-12-12 NZ NZ568946A patent/NZ568946A/en unknown
- 2006-12-12 PT PT68499516T patent/PT1984344E/pt unknown
- 2006-12-12 KR KR1020087015697A patent/KR101360621B1/ko active IP Right Grant
- 2006-12-12 DK DK06849951.6T patent/DK1984344T3/da active
- 2006-12-12 PL PL06849951T patent/PL1984344T3/pl unknown
- 2006-12-12 WO PCT/US2006/047579 patent/WO2007089335A2/en active Application Filing
- 2006-12-12 CN CN2006800499070A patent/CN101351451B/zh active Active
- 2006-12-12 US US11/638,677 patent/US7723345B2/en active Active
- 2006-12-12 CA CA2635531A patent/CA2635531C/en not_active Expired - Fee Related
- 2006-12-12 EA EA200870127A patent/EA019879B1/ru not_active IP Right Cessation
- 2006-12-12 ES ES11005146.3T patent/ES2684821T3/es active Active
- 2006-12-12 AU AU2006337137A patent/AU2006337137B2/en active Active
- 2006-12-12 BR BRPI0620756-1A patent/BRPI0620756B1/pt active IP Right Grant
- 2006-12-12 JP JP2008548561A patent/JP5483883B2/ja active Active
- 2006-12-12 EP EP11005146.3A patent/EP2386547B1/en active Active
- 2006-12-12 CN CN201310082551.2A patent/CN103265495B/zh active Active
-
2008
- 2008-06-05 IL IL191998A patent/IL191998A/en active IP Right Grant
- 2008-06-30 EC EC2008008590A patent/ECSP088590A/es unknown
- 2008-07-28 NO NO20083324A patent/NO344848B1/no unknown
-
2009
- 2009-03-11 HK HK09102308.4A patent/HK1124841A1/xx unknown
-
2010
- 2010-03-30 US US12/750,278 patent/US8063057B2/en active Active
-
2011
- 2011-11-07 US US13/290,261 patent/US8629156B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112906A2 (en) * | 2004-05-21 | 2005-12-01 | Duke University | Method for augmenting the effects of serotonin reuptake inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006337137B2 (en) | Multicyclic amino acid derivatives and methods of their use | |
AU2008275179B2 (en) | Methods and compositions for treating pulmonary hypertension and related diseases and disorders | |
AU2008268409B2 (en) | Compositions comprising tryptophan hydroxylase inhibitors | |
AU2008268494A1 (en) | Methods of treating serotonin-mediated diseases and disorders | |
AU2008279426A1 (en) | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein | |
EP2533778A1 (en) | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease | |
CA2779681A1 (en) | Tryptophan hydroxylase inhibitors for the treatment of cancer | |
WO2010062829A1 (en) | Tryptophan hydroxylase inhibitors for treating osteoporosis | |
MX2008008483A (en) | Multicyclic amino acid derivatives and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-INVENTOR NAME FROM MARINELLI, BRENT TO MARINELLI, BRETT |
|
FGA | Letters patent sealed or granted (standard patent) | ||
NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO REQUEST AN EXTENSION OF TERM - PHARMACEUTICAL HAS BEEN EXTENDED TO 14 APR 2019 |
|
NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: XERMELO TELOTRISTAT ETHYL Filing date: 20180414 |
|
NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: XERMELO TELOTRISTAT ETHYL Filing date: 20180914 |
|
TH | Corrigenda |
Free format text: IN VOL 33 , NO 16 , PAGE(S) 2462 UNDER THE HEADING EXTENSIONS OF TERM OF STANDARD PATENT, SECTION 70 - APPLICATIONS FILED DELETE ALL REFERENCE TO 2006337137 |
|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 JUN 2019 |
|
NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: XERMELO TELOTRISTAT ETIPRATE Filing date: 20180914 |
|
TH | Corrigenda |
Free format text: IN VOL 33 , NO 18 , PAGE(S) 2739 UNDER THE HEADING EXTENSIONS OF TERM OF STANDARD PATENT, SECTION 70 - APPLICATIONS FILED DELETE ALL REFERENCE TO 2006337137 |
|
NDA | Extension of term for standard patent accepted (sect.70) |
Free format text: PRODUCT NAME: XERMELO TELOTRISTAT ETIPRATE Filing date: 20180914 |
|
NDB | Extension of term for standard patent granted (sect.76) |
Free format text: PRODUCT NAME: XERMELO TELOTRISTAT ETIPRATE Filing date: 20180914 Extension date: 20311212 |
|
PC | Assignment registered |
Owner name: TERSERA THERAPEUTICS LLC Free format text: FORMER OWNER(S): LEXICON PHARMACEUTICALS, INC. |